InMed制药公司的股东重新选举所有董事会成员,并于2025年12月17日批准了股份发行计划。 InMed Pharmaceuticals' shareholders re-elected all board members and approved a share issuance plan on December 17, 2025.

InMed制药公司于12月17日举行了2025年年度会议,35.43%的股份在其中占有。 InMed Pharmaceuticals held its 2025 annual meeting on December 17, with 35.43% of shares represented. 股东重新选举所有六位董事会成员,每人获得超过81%的支持,核准审计员CBIZ CPAs P.C.,支持一项计划,根据《备用公平购买协议》发放最多20%的共同股份,并遵守Nasdaq规则。 Shareholders re-elected all six board members, each receiving over 81% support, approved auditors CBIZ CPAs P.C., and backed a plan to issue up to 20% of common shares under a Standby Equity Purchase Agreement, complying with Nasdaq rules. 该公司针对CB1/CB2受体研制用于老年痴呆症、眼睛和皮肤的药物,指出其声明包括前瞻性风险。 The company, developing drugs for Alzheimer’s, eye, and skin conditions targeting CB1/CB2 receptors, noted its statements include forward-looking risks. 12月17日向SEDAR+提交了结果。 Results were filed with SEDAR+ on December 17.